---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-25-001901"
form_type: "8-K"
ticker: "AGPU"
cik: "0001446159"
company_name: "Axe Compute Inc."
filed_at: "2025-04-01T23:59:59+00:00"
generated_at: "2026-05-24T00:39:32.032967+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Predictive Oncology FY2024 loss $10.8M on $1.6M revenue; cash drops to $0.7M; merger with Renovaro pending

## Summary
- Revenue of $1.6M essentially flat YoY; loss from continuing ops of $10.8M.
- Cash and equivalents fell to $734,673 from $8.7M; stockholder deficit of ($202,610).
- Net loss per share from continuing ops improved 33% to $1.99.
- Raised $3M in early 2025 via asset sale, warrant exercises, and Renovaro financing.
- Still working toward definitive merger agreement with Renovaro after Jan LOI.

## SEC filing metadata
- accession: 0001171843-25-001901
- form_type: 8-K
- ticker: AGPU
- cik: 0001446159
- company_name: Axe Compute Inc.
- filed_at: 2025-04-01T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1446159/000117184325001901/0001171843-25-001901-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1446159/000117184325001901/f8k_033125.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-25-001901
- JSON: https://secwatch.observer/filing/0001171843-25-001901.json
- Plain text: https://secwatch.observer/filing/0001171843-25-001901.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.